PT  - JOURNAL ARTICLE
AU  - James M. Joers
AU  - Isaac M. Adanyeguh
AU  - Dinesh K. Deelchand
AU  - Diane H. Hutter
AU  - Lynn E. Eberly
AU  - Isabelle Iltis
AU  - Khalaf O. Bushara
AU  - Christophe Lenglet
AU  - Pierre-Gilles Henry
TI  - Spinal cord MRI and MRS Detect Early-stage Alterations and Disease Progression in Friedreich Ataxia
AID  - 10.1101/2022.01.28.22270048
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.28.22270048
4099  - http://medrxiv.org/content/early/2022/01/30/2022.01.28.22270048.short
4100  - http://medrxiv.org/content/early/2022/01/30/2022.01.28.22270048.full
AB  - Background Friedreich Ataxia (FRDA) is the most common hereditary ataxia. Atrophy of the spinal cord is one of the hallmarks of the disease. Magnetic resonance imaging (MRI) and spectroscopy (MRS) are powerful and non-invasive tools to investigate pathological changes in the spinal cord. A handful of studies have reported cross-sectional alterations in FRDA using MRI and diffusion MRI (dMRI) in FRDA. However, to our knowledge no longitudinal MRI, dMRI or MRS results have been reported in the spinal cord in FRDA.Objective To investigate early-stage cross-sectional alterations and longitudinal changes in the cervical spinal cord in FRDA, using a multimodal magnetic resonance (MR) protocol comprising morphometric (anatomical MRI), microstructural (dMRI), and neurochemical (1H MRS) assessments.Design We enrolled 28 early-stage individuals with FRDA and 20 age- and gender-matched controls (cross-sectional study). Disease duration at baseline was 5.5±4.0 years and Friedreich Ataxia Rating Scale (FARS) total neurological score at baseline was 42.7±13.6. Twenty-one FRDA participants returned for 1-year follow-up, and 19 of those for 2-year follow-up (cohort study). Each visit consisted in clinical assessments and MR scans. Controls were scanned at baseline only.Results At baseline, individuals with FRDA had significantly lower spinal cord cross-sectional area (−31%, p=4.10−17), higher eccentricity (+10%, p=5.10−7), lower total N-acetyl-aspartate (−36%, p=6.10−9) and higher myo-inositol (+37%, p=2.10−6) corresponding to a lower ratio tNAA/mIns (−52%, p=2.10−13), lower fractional anisotropy (−24%, p=10−9) as well as higher radial diffusivity (+56%, p=2.10−9), mean diffusivity (+35%, p=10−8) and axial diffusivity (+17%, p=4.10−5) relative to controls.Longitudinally, spinal cord cross-sectional area decreased by 2.4% per year relative to baseline (p=4.10−4), the ratio tNAA/mIns decreased by 5.8% per year (p=0.03), and fractional anisotropy showed a trend to decrease (−3.2% per year, p=0.08).Spinal cord cross-sectional area correlated strongly with clinical measures, with the strongest correlation coefficients found between cross-sectional area and Scale for the Assessment and Rating of Ataxia (SARA) (R=-0.55, p=7.10−6) and between cross-sectional area and FARS total neurological score (R=-0.60, p=4.10−7). Less strong but still significant correlations were found for fractional anisotropy and tNAA/mIns.Conclusion We report here the first quantitative longitudinal MR results in the spinal cord in FRDA. The largest longitudinal effect size was found for spinal cord cross-sectional area, followed by tNAA/mIns and fractional anisotropy. Our results provide direct evidence that abnormalities in the spinal cord result not solely from hypoplasia, but also from neurodegeneration, and show that disease progression can be monitored non-invasively in the spinal cord.Competing Interest StatementC.L. and P.G.H. received research grants from Minoryx Therapeutics. All other authors stated that they have no conflicts of interest to report.Funding StatementThis work was supported by primarily by the Friedreich Ataxia Research Alliance (FARA), with additional support from Ataxia UK, GoFAR, the CureFA Foundation and the Bob Allison Ataxia Research Center (BAARC). Aside from funding, FARA also assisted with recruitment of FRDA participants. The Center for Magnetic Resonance Research is supported by NIH grants P41EB027061 and P30NS076408. The 3 Tesla scanner upgrade was funded in part by NIH instrumentation grant 1S10OD017974.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the University of Minnesota gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors9HPT9-hole peg testADaxial diffusivityADLactivities of daily livingBLbaselineCrcreatineCRLBCramer-Rao lower boundsCSAcross-sectional areaCSFcerebrospinal fluiddMRIdiffusionMRI EPIecho-planar imagingFAfractional anisotropyFARSFriedreich ataxia rating scaleFRDAFriedreich AtaxiaGPCglycerophosphocholineMDmean diffusivitymInsmyo-inositolMRSmagnetic resonance spectroscopyNAAN-acetyl-aspartateNAAGN-acetyl-aspartyl-glutamatePChophosphocholinePCrphosphocreatineRDradial diffusivitySARAscale for the assessment and rating of ataxiaSCTspinal cord toolboxSNRsignal-to-noise ratioSRMstandardized response meantChototal cholinetCrtotal creatinetNAAtotal N-acetyl-aspartate